Tuberculosis (TB)

Policy statements

TB diagnostics and laboratory strengthening

The landscape of TB diagnostics continues to evolve, with new technologies at various stages in the product development pipeline. WHO follows a systematic process for development of policy recommendations, involving synthesis of the available data through systematic reviews, assessment of the evidence by a Guideline Development Group using the GRADE approach, and development of policy guidance for dissemination to Member States and other stake holders.

Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV - Policy update (2019)

Evaluation of centralized assays for TB detection and detection of resistance to rifampicin and isoniazid: WHO Technical Expert Consultation Report

Next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex

Drug susceptibility testing of medicines used in the treatment of tuberculosis

Critical concentrations for drug-susceptibility testing

Xpert MTB/RIF Ultra

The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin

The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis

The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs

Framework for implementing TB diagnostics


Framework for indicators and targets for laboratory strengthening under the End TB Strategy



Culture and drug susceptibility testing (DST)

Interferon-gamma release assays (IGRAs)

Commercial serodiagnostic tests

Organization and management

Definitions and reporting